The precision of PSMA PET/CT in detecting prostate cancer recurrence at lower PSA levels underscores its potential to significantly inform treatment decisions, particularly in the context of ultrasensitive PSA monitoring. This evidence concerns the gene FOLH1 and prostate carcinoma.